A Phase 3 interventional study of HL151 and Talion Tab in Pruritus, sponsored by Hanlim Pharm. Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2018-08-28.
Sponsored by Hanlim Pharm. Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Pruritus with a site in Korea, Republic of — 3 open to participants now, 3 under way, 2 of them phase 3. Pruritus · Korea, Republic of.
Among the 20 studies in Pruritus with a site in Korea, Republic of, this one is the 12th largest by enrollment, is the only one that started in 2017, is one of 10 in phase 3, and was the 10th registered.
491 studies on the registry are indexed under Pruritus; 94 are open to participants now.
Browse Pruritus studies →3 of the 20 studies in Pruritus with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Korea, Republic of, United States, Argentina and 2 more countries
Ages 18+
Pfizer · Sites in Korea, Republic of, United States, Bulgaria and 7 more countries
Ages 18+
Sanofi · Sites in Korea, Republic of, United States, Argentina and 10 more countries
Ages 18–90
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 189 is above the median of 60 across 423 interventional studies indexed under Pruritus.
Median enrollment 197 across the 20 interventional studies. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 10 most frequent:
Hanlim Pharm. Co., Ltd. is the lead sponsor of 50 studies on the registry; 8 are open to participants now.
Hanlim Pharm. Co., Ltd. has 1 study filed under Pruritus — fewer than ten, so there is no comparison to draw.
2 of the studies in Pruritus with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05263206Phase 3SanofiEfficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) | 2027-06-02 |
| NCT07219615PfizerA Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | 2026-12-25 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Pruritus with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
a Multicenter, Randomized, Double-blinded, Active-controlled, Parallel, Phase Ⅲ Study to Evaluate the Efficacy and Safety of HL151 versus Talion Tab. in Pruritus cutaneus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with pruritus due to the following diseases
① acute eczema, chronic eczema, monetary eczema, sebaceous deficiency eczema
② contact dermatitis, atopic dermatitis, seborrheic dermatitis, neurodermatitis
③ Acute prurigo (Strofus, Urticaria, lichen urticatus), subacute prurigo, chronic prurigo (nodular prurigo)
④ systemic skin pruritus, focal skin pruritus
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)
Drug: HL151
Comparator: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)
Drug: Talion Tab
2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)
2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)
Changes in VAS(Visual Analogue Scale) score at 2nd week after clinical drug administration compared to baseline
VAS score: 0 Point \~ 10 Point (asymptomatic \~ Maximum pruritus) Evaluation period: Visit 2 (0 week), Visit 3 (1 week), Visit 4 (2 weeks)
Time frame: Visit 2 (0 week), Visit 3 (1 week), Visit 4 (2 weeks)
Changes in VAS(Visual Analogue Scale) score at 1st week after clinical drug administration
VAS score: 0 Point \~ 10 Point (asymptomatic \~ Maximum pruritus) * Evaluation period: Visit 2 (0 week), Visit 3 (1 week)
Time frame: Visit 2 (0 week), Visit 3 (1 week)
Changes in VAS(Visual Analogue Scale) score at 1st and 2nd week(Day) after clinical drug administration compared to baseline
VAS score: 0 Point \~ 10 Point (asymptomatic \~ Maximum pruritus) * Evaluation period: Visit 2 (0 week), Visit 3 (1 week), Visit 4 (2 weeks
Time frame: Visit 2 (0 week), Visit 3 (1 week), Visit 4 (2 weeks
Changes in VAS(Visual Analogue Scale) score at 1st and 2nd week after clinical drug administration compared to baseline
VAS score: 0 Point \~ 10 Point (asymptomatic \~ Maximum pruritus) * Evaluation period: Visit 2 (0 week), Visit 3 (1 week), Visit 4 (2 weeks)
Time frame: Visit 2 (0 week), Visit 3 (1 week), Visit 4 (2 weeks)
Investigator's assessment of overall treatment(Cochran-Mantel-Haenszel method)
VAS score: 0 Point \~ 10 Point (asymptomatic \~ Maximum pruritus) * Evaluation period: Visit 4 (2 weeks)
Time frame: Visit 4 (2 weeks)
Ran from May 2017 to primary completion in Nov 2017, 5 months.
Of 42 industry-sponsored phase 3 interventional studies under Pruritus, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 26. This study's 5 months is below that.
Counting every sponsor, half of 48 studies reached it within 19 months; a quarter within 12 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HL151